Treatment failure rate · patients with osteoarthritis of the knee
It is very uncertain whether closing wedge high tibial osteotomy (CW‐HTO) changes treatment failure rate compared with unicompartmental knee arthroplasty (very low certainty).
1 finding from 1 review
Pain · patients with osteoarthritis of the knee
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Restoration survival · Permanent posterior teeth with single-surface cavities
The pooled survival rate was 93% at 2 years.
6 findings from 1 review
Show 3 more findings
Restoration survival · Permanent posterior teeth with multiple-surface cavities
The pooled survival rate was 41% at 2 years.
3 findings from 1 review
Survival percentage 41 [18, 67]
1 study
GRADE not reported
Survival percentage 86 [59, 98]
3 studies
GRADE not reported
Survival percentage 77 [56, 92]
1 study
GRADE not reported
Restoration survival · Primary posterior teeth with single-surface cavities
The pooled survival rate was 95% at 1 year.
3 findings from 1 review
Restoration survival · Primary posterior teeth with multiple-surface cavities
The pooled survival rate was 62% at 2 years.
3 findings from 1 review
Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with standard‐low dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with low dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in myocardial infarction compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing cardiovascular disease, men and women
It is very uncertain whether homocysteine‐lowering interventions (high dose) changes stroke compared with homocysteine‐lowering interventions (low dose) (very low certainty).
1 finding from 1 review
Death by any cause · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in death by any cause compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Cancer · people with or without existing cardiovascular disease, men and women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found